Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2
2(28.6%)
Phase 4
2(28.6%)
Phase 3
1(14.3%)
Early Phase 1
1(14.3%)
N/A
1(14.3%)
7Total
Phase 2(2)
Phase 4(2)
Phase 3(1)
Early Phase 1(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT00574834Early Phase 1Terminated

Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes

Role: collaborator

NCT01030406Phase 2Completed

Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users

Role: collaborator

NCT00652314Phase 4Completed

Evaluation of an Absorbable Surgical Hemostatic Agent: Thrombi-Gel® Versus Gelfoam-Thrombin

Role: collaborator

NCT00814333Not ApplicableTerminated

Trial Comparing Outcomes With Merocel Packing or Thrombin-JMI for Anterior Epistaxis

Role: collaborator

NCT00425256Phase 2Completed

Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

Role: collaborator

NCT00095654Phase 3Completed

The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial

Role: collaborator

NCT00473174Phase 4Completed

Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension

Role: collaborator

All 7 trials loaded